All News
Filter News
Found 10,117 articles
-
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
5/16/2019
Actinium Pharmaceuticals, Inc. announced that an abstract pertaining to its lead product candidate, Iomab-B, which is being studied in the pivotal Phase 3 SIERRA study, will be presented via poster at the 2019 ASCO or American Society of Clinical Oncology Annual Meeting that is being held from May 31st – June 4th at McCormick Place, in Chicago.
-
Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
5/16/2019
New data at ASCO include more than double the patients previously reported; median overall survival still not reached with a median follow-up of up to 17 months
-
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
5/16/2019
Oncopeptides AB announced that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association meeting.
-
Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting
5/16/2019
Oncopeptides AB announced that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma have been selected for poster presentation at the 2019 American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4 in Chicago.
-
Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
5/15/2019
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher
-
AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients
5/15/2019
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
-
Krispy Krunchy® Announces Groundbreaking Partnership with The Leukemia & Lymphoma Society
5/15/2019
Krispy Krunchy Foods, LLC, will be donating 100% of their corporate profits from the sale of the Krispy Krunchy Chicken® Sandwich to The Leukemia & Lymphoma Society (LLS) where the money will go directly to fund research, help families, and save lives
-
X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia
5/15/2019
Mavorixafor selected for LLS’s Therapy Acceleration Program® (TAP)
-
Janssen to Present Data from Robust Oncology Portfolio and Pipeline at the 2019 ASCO Annual Meeting, Including Best of ASCO Selections
5/15/2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the latest research from its robust oncology portfolio and pipeline to be presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago from May 31 to June 4.
-
Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/15/2019
First Presentation of Data from EV-201 Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer Featured in an Oral Session on Monday, June 3rd
-
Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019
5/15/2019
Sanofi's oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering against a renewed strategy to address difficult-to-treat and difficult-to-eradicate cancers, including certain types of multiple myeloma, skin cancer, breast cancer, and lung cancer.
-
Amgen Showcases Oncology Pipeline At ASCO 2019
5/15/2019
Amgen announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago, May 31-June 4, 2019.
-
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
5/15/2019
Sutro Biopharma, Inc. reported its financial results for the quarter ended March 31, 2019.
-
Celgene to Highlight New and Updated Hematology and Oncology Clinical Data at Upcoming American Society of Clinical Oncology (ASCO) 2019 Annual Meeting
5/15/2019
Presentations include innovative cancer research, including novel CAR T technology, as well as key disease areas, including myelofibrosis and multiple myeloma
-
New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting
5/15/2019
Merck, known as MSD outside the United States and Canada, announced that new research from the company’s broad oncology clinical development program will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago from May 31-June 4.
-
Be The Match BioTherapies® Announces Collaboration with Poseida Therapeutics to Support Development of Life-Saving Cellular Therapies
5/14/2019
Be The Match BioTherapies will provide end-to-end support services to accelerate clinical development of Poseida’s autologous BCMA and PSMA CAR-T programs
-
Precision for Medicine To Provide Real-Time Laboratory Testing Services In Unique Lymphoma Patient Stratification Study
5/14/2019
The novel study will utilize Precision for Medicine's Houston-based CLIA certified lab to conduct real-time stratification studies on a specially selected group of B-Cell Lymphoma patients
-
Malin Corporation plc: Poseida receives FDA orphan drug designation for lead candidate and FDA approval of fully outpatient dosing in Phase 2 clinical trial
5/14/2019
Malin Corporation plc. (Euronext Growth Dublin:MLC) (“Malin”), a company investing in highly innovative life sciences companies, is pleased to note that Poseida Therapeutics Inc. (“Poseida”), one of Malin’s Priority Assets, has announced the US Food and Drug Administration (“FDA”) has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma.
-
DCprime Presents Comprehensive Preclinical Results Supporting Lead Clinical Candidate DCP-001
5/14/2019
DCprime today announced presentations of additional preclinical data sets for its lead program, DCP-001, at the 7th CCBIO Annual Symposium and the 2019 CIMT Annual Meeting.
-
BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
5/14/2019
BioLineRx Ltd. reports its financial results for the quarter ended March 31, 2019 and provided a corporate update.